On November 16, 2018, Harry D’Andrea, a director of OpGen, Inc, resigned from the Board of Directors and from all committees of the Board of Directors on which he served. Mr. D’Andrea served as a member of and Chair of the Audit Committee. There was no disagreement between Mr. D’Andrea and the Company leading to his decision to resign. Also on November 16, 2018, the Board appointed Tina Nova to serve as a member of the Audit Committee of the Board of Directors. The Board assessed her qualifications for serving in such capacity, including her roles as the chief executive officer of a number of companies and her prior service on the Audit Committee of other publicly traded companies, and re-assessed her status as an independent member of the Board of Directors. Dr. Nova was confirmed as an independent member of the Board of Directors with the necessary financial statement expertise to serve as a member of the Audit Committee.
OpGen, Inc. (OpGen) is a precision medicine company that uses molecular diagnostics and informatics to combat infectious diseases. The Company, through its subsidiaries, is focused on developing and commercializing molecular microbiology solutions helping to guide clinicians with actionable information infections caused by multidrug-resistant microorganisms (MDROs). The Companyâs product portfolio includes Unyvero, Acuitas AMR Gene Panel, and the ARES Technology Platform including ARESdb, next-generation sequencing (NGS) technology and AI-powered bioinformatics solutions for AMR surveillance, outbreak analysis, and antibiotic response prediction including ARESiss, ARESid, ARESasp, and AREScloud, as well as the Curetis CE- in vitro diagnostics (IVD)-marked polymerase chain reaction (PCR)-based severe acute respiratory syndrome (SARS)-CoV-2 test kit. The Companyâs subsidiaries include Curetis GmbH and Ares Genetics GmbH.
OPGEN, INC. 